Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Janet Pope Janetbirdope
3 months 2 weeks ago
I think you can guess why in the USA many Pts with
#immunesuppressives
In #chronic #diseases?
IT IS the 💵 cost of #medications in uninsured pts
#EULAR2024 @RheumNow @ACRheum @eular_org
A call for #equitable #fair #pharmacare
#EULARBEST https://t.co/VRnmKrf3DZ
David Liew drdavidliew
3 months 2 weeks ago
We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives.
Something to be very proud of. Let’s not forget that!
5y mortality from DANBIO 🇩🇰
(still, we still have work to do in seropos RA in men!)
#EULAR2024 OP0162 @RheumNow https://t.co/RfvABXhPvS
In the wake of the EULAR 2023 guidelines on the management of SLE, it is perhaps pertinent that the EULAR 2024 congress features three abstracts from a large integrated analysis from five international Phase 3 belimumab trials in adults with active SLE (BLISS-76, BLISS-52, North East Asia, EMBRACE and BLISS-SC). Participants were randomised to belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard
Dr. John Cush RheumNow
3 months 2 weeks ago
Join us live for the RheumNow Daily Recap Series, starting today at 12 PM EST! Get the latest insights and updates from #EULAR2024. Don’t miss out on expert analysis and engaging discussions. See you there! https://t.co/pnEI9WKssL
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0181- What are the best drugs to treat D2T RA?
In this cohort of 185 pts, switching biologic or JAKi improved disease activity & was considered to be effective for patients with D2TRA, regardless of mode of action
@RheumNow #EULAR2024
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0165- incidence & risk factors of D2T RA in an early RA cohort
Factors assoc with D2T RA:
🩸 Seropositivity
🦴 Erosions
📈 Disease activity
📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis
#EULAR24 @RheumNow
Janet Pope Janetbirdope
3 months 2 weeks ago
Can you ⬇️
#Glucocorticoids or #immunesuppressive in #SLE & change am’t of damage
From Asia Pacific #lupus collab
(Biologics not included)
Compared 7.5 mg #prednisone or less
Or DMARD
1/2 flared after LLDAS
⬇️dose didn’t prevent damage
#EULAR2024
@eular_org @RheumNow https://t.co/QmjEz87Cvw
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) @RheumNow #EULARBEST https://t.co/ArAzdLYiYY
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n>100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/q5olZgr6Pt
David Liew drdavidliew
3 months 2 weeks ago
I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events.
Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early!
#EULAR2024 OP0114 @karolinskainst @RheumNow https://t.co/Q8dIHiIYQk
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
#EULARBest
OP0156- validation & prevalence of D2T RA
Data from @BrighamResearch BRASS
In this cohort, the #EULAR definition of D2TRA correctly identified a subset of RA pts who have not achieved low disease activity despite multiple b/ts DMARD treatments
#EULAR2024 @RheumNow
